Regulation of the pharmaceutical market in the Western Balkan countries


  • Nia Masiukovich School of Health Sciences, University of Georgia


Regulation of the pharmaceutical market, reference price


The goal of the pharmaceutical policy of the governments of the Western Balkan countries was to harmonize the pharmaceutical legislation with the European Union. Drug regulatory mechanisms were introduced, simplifying requirements for drug registration, professional licensing, and pharmaceutical business operations. Ethical standards were reviewed, price controls were established, and drugs were actively included in national health insurance systems. To contain costs, a "positive drug list" with appropriate co-payments was introduced, as well as pooled purchases and open tenders to ensure lower prices. Nevertheless, there are a number of challenges: non-enforcement of rules and standards, limited access to medicinal products for low-income population, ineffective distribution of resources, incomplete distribution of drugs in the pharmacy network, lack of control over prescribing by doctors.


Siegmeier F, Büssgen M. (2022). Indication-wide drug pricing: Insights from the pharma market. J of Pharm Policy and Pract 15, 53.

Health resources—Health spending - OECD Data. Verfügbar unter: zitiert 10. März 2022.

Global Health Expenditure Database. 2021. Verfügbar unter: zitiert 27. August 2021.

IQVIA, The Global Use of Medicine in 2019 and Outlook to 2023. 2019. Verfügbar

unter: zitiert 27. August 2021.

Panteli D, Arickx F, Cleemput I, Dedet G, Eckhardt H, Fogarty E. (2016). Pharmaceutical regulation in 15 European countries review. Health Syst Transit 18(5):1–122.

Paris V, Belloni A. (2021). Value in Pharmaceutical Pricing. Verfügbar unter: https://www.oecd zitiert.

Lauenroth VD, Stargardt T. (2017). Pharmaceutical pricing in Germany: how is value setermined within the Scope of AMNOG? Value Health. 20(7):927–35.

Pieter Dylst, Arnold G Vulto, Steven Simoens. (2021). Reference pricing systems in Europe: characteristics and - GaBI Journal. Verfügbar unter: characteristics-and-consequences.html.

Vogler S, Schneider P, Zuba M, Busse R, Panteli D. (2021). Policies to encourage the use of biosimilars in European countries and their potential impact on pharmaceutical expenditure. Front Pharmacol 12:625296.

Mitkova Z, Vasileva M, Savova A, Manova M, Terezova S, Petrova G. (2020). Comparison of cardiovascular medicines prices in four European countries. Front Public Health 8:433.

Vokinger KN, Hwang TJ, Grischott T, Reichert S, Tibau A, Rosemann T. (2020). Prices and clinical benefit of cancer drugs in the USA and Europe: a cost-benefit analysis. Lancet Oncol. 21(5):664–70.

Hernandez I, Bott SW, Patel AS, Wolf CG, Hospodar AR, Sampathkumar S. (2018). Pricing of monoclonal antibody therapies: higher if used for cancer? Am J Manag Care 24(2):109–12.

Yang JJ, Pham AT, Maloney NJ, Aly O, Cheng K. (2021). Psoriasis drugs in the medicare population: dermatologists’ spending and prescription patterns. J Dermatolog Treat. 1–4.

Peter P, Lipska K. (2016). The rising cost of diabetes care in the USA. Lancet Diabetes Endocrinol Juni 4(6):479–80.

Moye-Holz D, Vogler S. (2021). Comparison of prices and affordability of cancer medicines in 16 countries in Europe and Latin America. Appl Health Econ Health Policy.

Morgan SG, Bathula HS, Moon S. (2020). Pricing of pharmaceuticals is becoming a major challenge for health systems. BMJ. 368:l4627.

Henschke C, Sundmacher L, Busse R. (2013). Structural changes in the German pharmaceutical market: price setting mechanisms based on the early benefit evaluation. Health Policy 109(3):263–9.

Stargardt T, Schreyögg J. (2006). Impact of cross-reference pricing on pharmaceutical prices: manufacturers’ pricing strategies and price regulation. Appl Health Econ Health Policy 5(4):235–47.

Mrazek M. and Frank, R. (2004) The off-patent pharmaceutical market. Chp. 14 p. 245 - 247 In: E. Mossialos M, Walley . Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality”. Maidenhead, Birkshire: Open University Press.

Mrazek M, Frank R. (2004) The off-patent pharmaceutical market. Chp. 14 p. 245 -247 In: E. Mossialos, M. Mrazek and T. Walley (Eds.) “Regulating pharmaceuticals in Europe: striving for efficiency, equity and quality”. Maidenhead, Birkshire: Open University Press.



How to Cite

Masiukovich, N. (2023). Regulation of the pharmaceutical market in the Western Balkan countries. Health Policy, Economics and Sociology, 7(1). Retrieved from